Faeth Therapeutics (FTH)
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offe...
- Open
- 33.000
- High
- 34.440
- Low
- 31.290
- Prev. Close
- 32.100
- Volume
- 433.89K
- Turnover
- 14.10M
- Avg Price
- 32.489
- Bid/Ask Ratio
- 0.00%
- Amplitude
- 9.81%
- 52wk High
- 37.900
- Volume Ratio
- 1.19
- Turnover Ratio
- 2.34%
Faeth Therapeutics Analyst Rating
View moreForecast & Rating
Aug 21, 2026Price forecast
$54.6470.74%
Forecast & RatingStrong buy
12analysts
- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · 2 days ago, 06:46 AM
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
- Tip Ranks · Aug 21 at 04:55 AM
Faeth Therapeutics Initiated at Buy on Oral Multi‑Node PI3K/AKT/mTOR Strategy; Analyst Sets $56 Price Target
- StockTitan · Aug 16 at 10:30 PM
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer | FTH Stock News
- StockTitan · Aug 13 at 10:30 PM
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments | FTH Stock News
- PUBT · Aug 7 at 03:00 PM
Faeth Therapeutics grants new-hire stock options for 11,000 shares at $25.5 each
- StockTitan · Aug 7 at 07:00 AM
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FTH Stock News
